Otros idiomas Nabriva Therapeutics plc

Acciones

NBRVF

IE000OZRGNV6

Diferido OTC Markets Otros sitios de cotización 15:33:08 03/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,0001 ^USD	0,00 %		0,00 %	+9.900,00 %

2023	Nabriva Therapeutics plc presenta los resultados del segundo trimestre y los seis meses finalizados el 30 de junio de 2023	CI
2023	Sumitomo Pharma Co., Ltd. (TSE:4506) adquirió activos y derechos relacionados con la lefamulina en China, Hong Kong, Macao y Taiwán a Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH y Nabriva Therapeutics Ireland Dac por 15 millones de dólares.	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	19/10/23
Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index	31/07/23
Sumitomo Pharma Co., Ltd. acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.	31/07/23
Nabriva Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	24/07/23
Arbutus Biopharma Promotes Dr. Karen Sims to Chief Medical Officer, Hires Christopher Naftzger as Chief Compliance Officer	10/07/23
Nabriva Therapeutics plc Appoints H. Michael Hogan as Chief Executive Officer	07/07/23
Nabriva Therapeutics plc Appoints Dave Maggio as Chief Financial Officer	07/07/23
Nabriva Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2023	22/05/23
NABRIVA THERAPEUTICS PLC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	17/04/23
Nabriva Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2022	17/04/23
Nabriva Therapeutics plc Auditor Raises 'Going Concern' Doubt	17/04/23
Merck : fin de l'accord de distribution avec Nabriva	06/02/23
Nabriva Therapeutics : Material Agreement - Form 8-K	06/02/23
NABRIVA THERAPEUTICS PLC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	06/02/23
NABRIVA THERAPEUTICS PLC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	20/01/23
Nabriva Therapeutics plc Appoints Christopher Naftzger as Interim Chief Executive Officer	20/01/23
Nabriva Therapeutics : Termination of Material Agreement - Form 8-K	09/01/23
NABRIVA THERAPEUTICS PLC : Termination of a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits (form 8-K)	09/01/23
Nabriva Therapeutics Provides Corporate Update	09/01/23
Health Care Up as Biogen Rises on Alzheimer's Drug Progress -- Health Care Roundup	06/01/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Nabriva Therapeutics plc

Acciones

NBRVF

IE000OZRGNV6

Otros idiomas

Filtros